The microtiter broth dilution method was employed to determine the in vitro susceptibility of 525 recent clinical isolates of anaerobic bacteria to sodium fusidate. The minimal inhibitory concentrations of sodium fusidate ranged from -0.06 to 1.0 ,ug/ml for 155 strains of anaerobic gram-positive rods and 130 strains of anaerobic gram-positive cocci. Minimal inhibitory concentrations ranging from s0.06 to 32 ,ug/ml were observed for 240 strains of anaerobic gram-negative rods.
Fusidic acid, produced by the fungus Fusidium coccineum, possesses a steroid structure and is chemically related to cephalosporin P1 (3) . Unlike the cephalosporins, which inhibit cell wall synthesis, fusidic acid inhibits bacterial protein synthesis by interfering with the translocation enzyme and inhibiting the binding of aminoacyl transfer ribonucleic acid to ribosomes (2) . Although a number of derivatives of fusidic acid have been prepared, only the sodium salt, sodium fusidate, possesses a significant degree of antibacterial activity.
Sodium fusidate is remarkable for its high activity against both penicillin-and methicillinresistant strains of Staphylococcus aureus (6) . Sodium fusidate is also very active against corynebacteria, but is poorly active against streptococci (4). Members of the genus Neisseria are the only aerobic gram-negative bacteria which are susceptible to this antibiotic (4). Other organisms previously shown to be susceptible to sodium fusidate include Clostridium tetani, C. perfringens, and Bacteroides fragilis (4, 7) . It was the reported susceptibility of these three anaerobic species which led us to investigate more extensively the activity of sodium fusidate against anaerobic bacteria.
MATERIALS AND METHODS
The in vitro activity of sodium fusidate against anaerobic bacteria was investigated by employing a microdilution modification of the microtiter procedure described by Thornsberry and Swenson (9 to 0.12 gAg/ml were prepared in sterile Schaedler broth supplemented with 5 ,ug of hemin per ml and 0.1 ug of menadione per ml; 50-pd amounts of these dilutions were dispensed aseptically into sterile U-bottom microtiter plates with a Dynatech MIC-2000 dispenser (Cooke Laboratories, Inc., Alexandria, Va.). Plates not used within 24 h of preparation were sealed in polyethylene bags and frozen at -70°C for a maximum of 6 weeks. Before inoculation, microtiter plates were placed in an anaerobic glove box and incubated at ambient temperature in an atmosphere of 85% N2, 10% H2, and 5% CO2 for 24 h.
All inocula were prepared and dispensed within the glove box environment. Inocula were prepared by suspending well-isolated colonies of each test strain from Schaedler sheep blood agar plates in 2 broth. The diluted organism suspension was mixed thoroughly, and 50 id of this suspension was added to each antibiotic well and to a growth control well containing 50 pl of the supplemented broth. The microtiter plates were inoculated by using a Minitek dispensing gun (BBL Microbiology Systems, Cockeysville, Md.). With inoculation, the final concentration of sodium fusidate contained within the 12 wells ranged between 128 and 0.06 /Ag/ml. The inoculated plates were sealed in polyethylene bags and incubated at 35°C for 48 h in an anaerobic glove box (Coy Manufacturing Co., Ann Arbor, Mich.) with an atmosphere of 85% N2, 10% C02, and 5% H2. The minimal inhibitory concentration (MIC) was read as the lowest concentration of the antibiotic which inhibited visible growth of each organism tested.
The stability of fusidic acid in the prepared microtiter trays was monitored by testing a strain of B. fragilis (for which the MIC of fusidic acid was known) on each day tests were performed. This quality control testing indicated that the antibiotic was stable for at least 6 weeks under the storage, prereduction, and incubation conditions employed. Sodium fusidate is usually administered by the oral route in a dosage of 500 mg three times a day. Godtfredsen and co-workers studied 10 patients administered this treatment regimen and found that the concentration in serum at 96 h ranged between 30 and 144 ,g/ml with a mean concentration of 71 ,ug/ml (4). A steady accumulation of fusidic acid during treatment was observed in most individuals (4) . When 500 mg of sodium fusidate is administered twice a day, the concentration in serum stabilizes at approximately 20 ILg,/ml and no accumulation of the antibiotic is observed (4) .
RESULTS
Sodium fusidate appears highly active in vitro against many anaerobic organisms. Only a few of the anaerobes tested (B. fragilis, B. thetaiotaomicron, and F. necrophorum) demonxsrated MICs of from 16 to 32 ,ug of sodium fusidate per ml. When our observations are combined with the known pharmacokinetic properties of fusidic acid, it appears that future studies in animal models might be indicated to investigate the in vivo effectiveness of this compound for the treatment of anaerobic infections.
